Viracta Therapeutics (STU:RYIS) EV-to-EBIT : -0.31 (As of May. 27, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Viracta Therapeutics's Enterprise Value is €12.59 Mil. Viracta Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-40.96 Mil. Therefore, Viracta Therapeutics's EV-to-EBIT for today is -0.31.

The historical rank and industry rank for Viracta Therapeutics's EV-to-EBIT or its related term are showing as below:

STU:RYIS' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.47 Med: 0 Max: 0.56
Current: -0.31

During the past 4 years, the highest EV-to-EBIT of Viracta Therapeutics was 0.56. The lowest was -4.47. And the median was 0.00.

STU:RYIS's EV-to-EBIT is ranked worse than
100% of 424 companies
in the Biotechnology industry
Industry Median: 10 vs STU:RYIS: -0.31

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Viracta Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was €24.25 Mil. Viracta Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-40.96 Mil. Viracta Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -168.87%.

Viracta Therapeutics EV-to-EBIT Historical Data

The historical data trend for Viracta Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics EV-to-EBIT Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-0.38

0.09

0.01

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial												-0.24	-0.25	-0.18	0.01	-0.56

Competitive Comparison of Viracta Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Viracta Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's EV-to-EBIT falls into.

Viracta Therapeutics EV-to-EBIT Calculation

Viracta Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	12.586	/	-40.958
	=	-0.31

Viracta Therapeutics's current Enterprise Value is €12.59 Mil.
Viracta Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-40.96 Mil.

Viracta Therapeutics (STU:RYIS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Viracta Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-40.958	/	24.25359
	=	-168.87 %

Viracta Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was €24.25 Mil.
Viracta Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-40.96 Mil.

Viracta Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics (STU:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (STU:RYIS) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

VIRX:USA

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

Viracta Therapeutics (STU:RYIS) Headlines

No Headlines